INTRODUCING A NEW OPTION FOR DRAVET SYNDROME

FINTEPLA is now an FDA approved treatment for people with Dravet syndrome age 2 and older.

FINTEPLA will be available late July.

Read about the FDA approval of FINTEPLA

Learn more

Get information about FINTEPLA

Important Safety Information

Indication

FINTEPLA can cause serious side effects, including:

  1. Problems with the valves in the heart (valvular heart disease) and high blood pressure in the arteries of the lungs (pulmonary arterial hypertension) have been associated with fenfluramine, the active ingredient in FINTEPLA. Your healthcare provider will do a test called an echocardiogram to check your heart and for high blood pressure in the arteries of the lungs before you start taking FINTEPLA, again every 6 months during treatment, and one time 3 to 6 months after you take your last dose of FINTEPLA.
  • FINTEPLA is a prescription medicine used to treat the seizures associated with Dravet syndrome in patients 2 years of age and older.
  • FINTEPLA is a federally controlled substance (C-IV) because it contains fenfluramine. Keep FINTEPLA in a safe place to prevent misuse, abuse, and protect it from theft. Never give your FINTEPLA to anyone else, because it may harm them. Selling or giving away this medicine is against the law. Tell your healthcare provider if you have abused or been dependent on alcohol, prescription medicines, or street drugs.
  • It is not known if FINTEPLA is safe and effective in children less than 2 years of age.
Loading...